Acute Pharmacokinetics of Memantine in the Mouse

被引:7
作者
Saab, Bechara J.
Roder, John C.
机构
[1] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada
[3] Univ Toronto, Program Neurosci, Toronto, ON, Canada
关键词
Memantine; Learning and memory; Mass spectroscopy; Alzheimer; Amantadine; acute; Blood; Brain; Pharmacokinetics; NMDA RECEPTOR ANTAGONIST; ALZHEIMERS-DISEASE; MICE; RAT; HIPPOCAMPUS; CORTEX; MEMORY;
D O I
10.1159/000332829
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of memantine, a widely prescribed medication in the United States and the European Union for the treatment of moderate-to-severe Alzheimer's disease (AD), have not been well explored in the mouse. Memantine is a highly unspecific blocker of many channels and how memantine may be of benefit in AD remains a mystery. Therefore, the investigation of memantine in the mouse, the most commonly chosen subject for modeling AD, has strong potential to lead to better therapies. Here, we present an acute pharmacokinetic analysis of memantine in mouse brain tissue and blood serum for a variety of experimentally relevant doses. The data help shed light on the mechanism of memantine action in vivo, and demonstrate that subcutaneous doses above 10 mg/kg in the mouse are most likely not therapeutically relevant to the human. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:284 / 287
页数:4
相关论文
共 22 条
  • [1] Memantine blocks α7*nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons
    Aracava, Y
    Pereira, EFR
    Maelicke, A
    Albuquerque, EX
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) : 1195 - 1205
  • [2] Probing the Biology of Alzheimer's Disease in Mice
    Ashe, Karen H.
    Zahs, Kathleen R.
    [J]. NEURON, 2010, 66 (05) : 631 - 645
  • [3] Memantine Dosing in Patients With Dementia
    Dolder, Christian
    Nelson, Michael
    McKinsey, Jonathan
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (02) : 170 - 173
  • [4] Drever BD, 2007, J ALZHEIMERS DIS, V12, P319
  • [5] Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice
    Fredriksson, A
    Danysz, W
    Quack, G
    Archer, T
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2001, 108 (02) : 167 - 187
  • [6] ONCE-DAILY MEMANTINE: PHARMACOKINETIC AND CLINICAL CONSIDERATIONS
    Gomolin, Irving H.
    Smith, Candace
    Jeitner, Thomas M.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 (09) : 1812 - 1813
  • [7] Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists
    Hesselink, MB
    De Boer, AG
    Breimer, DD
    Danysz, W
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1999, 106 (5-6) : 409 - 421
  • [8] CEREBROSPINAL-FLUID AND SERUM CONCENTRATIONS OF THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST MEMANTINE IN MAN
    KORNHUBER, J
    QUACK, G
    [J]. NEUROSCIENCE LETTERS, 1995, 195 (02) : 137 - 139
  • [9] Memantine treatment reduces the expression of the K+/Cl- cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABAA receptor activation in mice
    Molinaro, Gemma
    Battaglia, Giuseppe
    Riozzi, Barbara
    Di Menna, Luisa
    Rampello, Liborio
    Bruno, Valeria
    Nicoletti, Ferdinando
    [J]. BRAIN RESEARCH, 2009, 1265 : 75 - 79
  • [10] Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: Involvement of dopamine D2 and 5-HT2A receptors
    Nakaya, Kota
    Nakagawasai, Osamu
    Arai, Yuichiro
    Onogi, Hiroshi
    Sato, Atsushi
    Niijima, Fukie
    Tan-No, Koichi
    Tadano, Takeshi
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2011, 218 (01) : 165 - 173